Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciad724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Donelly A van Schalkwyk und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. Hauptthemen laut MEDLINE: Antimalarials, Artemisinins, Malaria, Malaria, Falciparum. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, UK Health Security Agency, UK Research and Innovation.
Abstract (Originalsprache)
Background
Recent cases of clinical failure in malaria patients in the United Kingdom (UK) treated with artemether-lumefantrine have implications for malaria chemotherapy worldwide.
Methods
Parasites were isolated from an index case of confirmed Plasmodium falciparum treatment failure after standard treatment, and from comparable travel-acquired UK malaria cases. Drug susceptibility in vitro and genotypes at 6 resistance-associated loci were determined for all parasite isolates and compared with clinical outcomes for each parasite donor.
Results
A traveler, who returned to the UK from Uganda in 2022 with Plasmodium falciparum malaria, twice failed treatment with full courses of artemether-lumefantrine. Parasites from the patient exhibited significantly reduced susceptibility to artemisinin (ring-stage survival, 17.3% [95% confidence interval {CI}, 13.6%–21.1%]; P < .0001) and lumefantrine (effective concentration preventing 50% of growth = 259.4 nM [95% CI, 130.6–388.2 nM]; P = .001). Parasite genotyping identified an allele of pfk13 encoding both the A675V variant in the Pfk13 propeller domain and a novel L145V nonpropeller variant. In vitro susceptibility testing of 6 other P. falciparum lines of Ugandan origin identified reduced susceptibility to artemisinin and lumefantrine in 1 additional line, also from a 2022 treatment failure case. These parasites did not harbor a pfk13 propeller domain variant but rather the novel nonpropeller variant T349I. Variant alleles of pfubp1, pfap2mu, and pfcoronin were also identified among the 7 parasite lines.
Conclusions
We confirm, in a documented case of artemether-lumefantrine treatment failure imported from Uganda, the presence of pfk13 mutations encoding L145V and A675V. Parasites with reduced susceptibility to both artemisinin and lumefantrine may be emerging in Uganda.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
- UK Health Security Agency Malaria Reference Laboratory, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
- Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
- Department of Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
ORCID-Profile: Colin J Sutherland
Förderung
- Medical Research Council
- UK Health Security Agency
- UK Research and Innovation
Zitieren
APA
van Schalkwyk, D. A., Pratt, S., Nolder, D., Stewart, L. B., Liddy, H., Muwanguzi-Karugaba, J., Beshir, K. B., Britten, D., Victory, E., Rogers, C., Millard, J., Brown, M., Nabarro, L. E., Taylor, A., Young, B. C., Chiodini, P. L., & Sutherland, C. J. (2024). Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad724
Vancouver
van Schalkwyk DA, Pratt S, Nolder D, Stewart LB, Liddy H, Muwanguzi-Karugaba J, et al. Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad724
BibTeX
@article{vanSchalkwyk2024,
author = {van Schalkwyk, Donelly A and Pratt, Sade and Nolder, Debbie and Stewart, Lindsay B and Liddy, Helen and Muwanguzi-Karugaba, Julian and Beshir, Khalid B and Britten, Dawn and Victory, Emma and Rogers, Claire and Millard, James and Brown, Michael and Nabarro, Laura E and Taylor, Andrew and Young, Bernadette C and Chiodini, Peter L and Sutherland, Colin J},
title = {Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciad724}
}
EUVIMED